Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML-Reference-Cited by-同舟云学术

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

Published:2019-10-31 Issue:18 Volume:381 Page:1728-1740
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Perl Alexander E.¹,Martinelli Giovanni¹,Cortes Jorge E.¹,Neubauer Andreas¹,Berman Ellin¹,Paolini Stefania¹,Montesinos Pau¹,Baer Maria R.¹,Larson Richard A.¹,Ustun Celalettin¹,Fabbiano Francesco¹,Erba Harry P.¹,Di Stasi Antonio¹,Stuart Robert¹,Olin Rebecca¹,Kasner Margaret¹,Ciceri Fabio¹,Chou Wen-Chien¹,Podoltsev Nikolai¹,Recher Christian¹,Yokoyama Hisayuki¹,Hosono Naoko¹,Yoon Sung-Soo¹,Lee Je-Hwan¹,Pardee Timothy¹,Fathi Amir T.¹,Liu Chaofeng¹,Hasabou Nahla¹,Liu Xuan¹,Bahceci Erkut¹,Levis Mark J.¹

Affiliation:

1. From the Abramson Cancer Center, University of Pennsylvania (A.E.P.), and Thomas Jefferson University (M.K.) — both in Philadelphia; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola (G.M.), L. and A. Seràgnoli Institute of Hematology, Bologna University Medical School, Bologna (S.P.), Ospedali Riuniti Villa Sofia-Cervello, Palermo (F.F.), and IRCCS San Raffaele Scientific Institute, Milan (F.C.) — all in Italy;...

Funder

Astellas Pharma US

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1902688

Cited by 880 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives;European Journal of Medicinal Chemistry;2024-11

2. Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia;Leukemia Research;2024-10

3. Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations;Expert Review of Hematology;2024-09-13

4. Management of Acute Myeloid Leukemia in Patients under 60 Years of Age;Advances in Hematological Malignancies [Working Title];2024-09-11

5. Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia;npj Precision Oncology;2024-09-10